D. E. Shaw & Co., Inc. Neu Base Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $30,681 - $72,212	-37,416 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.26 - $2.95 $47,144 - $110,377	37,416 New	37,416 $70,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $116,482 - $187,268	-44,801 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $43,075 - $62,703	-13,173 Reduced 22.72%	44,801 $162,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $177,166 - $280,865	-38,265 Reduced 39.76%	57,974 $278,000

Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $381,153 - $680,788	55,080 Added 133.82%	96,239 $711,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $284,820 - $380,720	41,159 New	41,159 $288,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.